DNA-PK inhibitors

Inventors: John Patrick Maxwell (Hingham, MA); Paul S. Charifson (Framingham, MA); Qing Tang (Acton, MA); Steven M. Ronkin (Watertown, MA); Katrina Lee Jackson (Cambridge, MA); Albert Charles Pierce (Cambridge, MA); David J. Lauffer (Stow, MA); Pan Li (Lexington, MA); Simon Giroux (Cambridge, MA); Jinwang Xu (Framingham, MA); Kevin Michael Cottrell (Cambridge, MA); Mark A. Morris (Somerville, MA); Nathan D. Waal (Cambridge, MA); John J. Court (Littleton, MA); Wenxin Gu (Concord, MA); Hongbo Deng (Southborough, MA)

Assignee: Vertex Pharmaceuticals Incorporated

A61K31/5377 A61K31/506 A61K31/5386 C07D241/40 C07D241/42 C07D241/44 C07D271/12 C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D405/12 C07D405/14 C07D413/04 C07D413/12 C07D413/14 C07D417/12 C07D471/04 C07D473/40 C07D475/00 C07D487/04 C07D491/048 C07D491/052 C07D491/056 C07D491/08 C07D498/08 C07D513/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,786,512
App. No.: 16/282,083
Granted: Sep 29, 2020
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Claims (10)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is of formula:

3. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt.

4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5. A compound of formula:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 , wherein the compound is of formula:

7. The compound of claim 5 , wherein the compound is a pharmaceutically acceptable salt.

8. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 5 , or a pharmaceutically acceptable salt thereof.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2019

From: XU, JINWANG; COTTRELL, KEVIN M.; MORRIS, MARK A.; WAAL, NATHAN D.; COURT, JOHN J.; GU, WENXIN; DENG, HONGBO

To: VERTEX PHARMACEUTICALS INCORPORATED

Reel/Frame 048829/0458 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2019

From: MAXWELL, JOHN PATRICK; CHARIFSON, PAUL S.; TANG, QING; RONKIN, STEVEN M.; JACKSON, KATRINA LEE; PIERCE, ALBERT CHARLES; LAUFFER, DAVID J.; LI, PAN; GIROUX, SIMON

To: VERTEX PHARMACEUTICALS INCORPORATED

Reel/Frame 048830/0196 →

Continuity (5)

Division 15659306 · Jul 25, 2017

Continuation 15148229 · May 6, 2016

Division 14205508 · Mar 12, 2014

Provisional Application 61777816 · Mar 12, 2013

Related Publication 20190255062A1 · Aug 22, 2019

Cited By (1)

US 12,251,387